Occurrence and susceptibility rates among urinary tract infection pathogens from Europe: a seven-year report from the SENTRY Antimicrobial Surveillance Program (19972000, 2003)
Abstract number: 1733_629
Moet G., Stilwell M., Jones R.
Objectives: To report the occurrence and susceptibility (S) rates for pathogens causing urinary tract infection (UTI) isolated from medical centres in Europe, Turkey, and Israel. The S rates were compared by CLSI and EUCAST breakpoints. The SENTRY Antimicrobial Surveillance Program was utilised as the platform for collecting urine culture isolates during 5 years out of 10 year period that the programme has been in existence.
Methods: A total of 4,507 strains (50 consecutive, non-duplicate per site) were collected from 42 medical centres in 19 countries in Europe, Turkey and Israel (19972000, 2003). During the 5 years 31 locations participated in 3 or more years. All isolate identifications were confirmed and S testing performed in a central laboratory using reference broth microdilution methods (M7-A7) and interpretive criteria of CLSI and EUCAST (2006). ESBL phenotype rates were as determined by CLSI criteria.
Results: The 5 most frequent pathogens accounted for 83.3% of the total CA-UTI and the top 7 for 90.0%. These 7 pathogens displayed little change in occurrence rates over the 7 year period. Escherichia coli remained the dominant UTI pathogen at nearly 50% while enterococci showed a slight decrease from 11.7 to 10.1%. Variations in 1999 were greater due to only 9 participating sites (small sample size). Among commonly isolated Enterobacteriaceae, carbapenems were the most active agents ranging from 99.1% to 100.0% S; lower S was noted for ciprofloxacin (7789%) and trimethoprim/sulfamethoxazole (T/S; 6378%). Ceftazidime S rates for Klebsiella, E. coli, and Proteus mirabilis were 80.7, 97.2, 95.5% (CLSI) and lower at 76.9, 94.7, 92.5% (EUCAST), respectively. ESBL phenotype rates were 24.0, 5.3, and 7.2% for the same organism groups. Polymyxin B was active against Pseudomonas aeruginosa at 99% S, followed by carbapenems and piperacillin/tazobactam at 84% and amikacin at 83%. Vancomycin, teicoplanin, and linezolid remained active against enterococci (99% S).
Conclusions: This comprehensive report from the SENTRY Program covering 7 years of UTI sampling in Europe, reports minor variation in the most common pathogens between the sample intervals but with significant S differences noted among monitored countries. Emerging resistance is limiting the usefulness of commonly prescribed UTI agents including T/S and FQ, forcing reliance on more potent parenteral broad-spectrum agents and the additional problems inherent in their use.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|